Journal Article10.1016/J.DIAGMICROBIO.2018.01.008
In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
42
TL;DR: Fosfomycin may be an adjuvant and enhance the inhibition of cell wall synthesis of carbapenem-resistant A. baumannii when combined with imipenem.
read more
About: This article is published in Diagnostic Microbiology and Infectious Disease. The article was published on 15 Jan 2018. The article focuses on the topics: Imipenem & Fosfomycin.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Luigia Scudeller,Elda Righi,Margherita Chiamenti,Damiano Bragantini,Giulia Menchinelli,Paolo Cattaneo,Christian G. Giske,Thomas P. Lodise,Maurizio Sanguinetti,Laura J. V. Piddock,Francois Franceschi,Sally Ellis,Elena Carrara,Alessia Savoldi,Evelina Tacconelli,Evelina Tacconelli +15 more
TL;DR: In this paper, a systematic review and meta-analysis was performed including pharmacokinetic/pharmacodynamic (PK/PD) and time-kill (TK) studies examining the in vitro efficacy of antibiotic combinations against carbapenem-resistant Gram-negative bacilli (CR-GNB) infections.
72
Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study.
Alessandro Russo,Matteo Bassetti,Valeria Bellelli,Luigi Bianchi,Federica Marincola Cattaneo,Stefania Mazzocchetti,Elena Paciacconi,Fabrizio Cottini,Arcangelo Schiattarella,Giuseppe Tufaro,Francesco Sabetta,Alessandro D'Avino +11 more
TL;DR: This real-life clinical experience concerning the therapeutic approach to severe pneumonia caused by MDR-AB provides useful suggestions to clinicians, showing the use of different antibiotic regimens with a predominant role for fosfomycin.
Predominance of international clone 2 multidrug-resistant Acinetobacter baumannii clinical isolates in Thailand: a nationwide study
Piyatip Khuntayaporn,Pohnvipa Kanathum,Jantana Houngsaitong,Preecha Montakantikul,Krit Thirapanmethee,Mullika Traidej Chomnawang +5 more
TL;DR: In this paper, the distribution of antimicrobial resistance genes in the bacterial population in Thailand was investigated at a country-wide level, and a total of 135 nonrepetitive Acinetobacter baumannii isolates collected from tertiary care hospitals across 5 regions of Thailand were examined for antibiotic susceptibility, resistance genes, and sequence types.
Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies.
Roberta Maria Antonello,Luigi Principe,Alberto Enrico Maraolo,Valentina Viaggi,Riccardo Pol,Massimiliano Fabbiani,Francesca Montagnani,Antonio Lovecchio,Roberto Luzzati,Stefano Di Bella +9 more
TL;DR: Fosfomycin-based antibiotic associations benefit from increase in the bactericidal effect and prevention of antimicrobial resistances, and the presence of synergistic interactions and the nearly total absence of antagonisms, make fosFomycin a good partner drug in clinical practice.
Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit.
Jingyi Shi,Ting Sun,Yun Cui,Chunxia Wang,Fei Wang,Yiping Zhou,Huijie Miao,Yijun Shan,Yucai Zhang +8 more
TL;DR: This retrospective study included 102 pediatric patients who developed MDR/XDR Acinetobacter baumannii infection in the pediatric intensive care unit (PICU) of Shanghai Children’s Hospital in China from December 2014 to May 2018, and indicated that bloodstream and central nervous system infection accounted for high risk of death.
References
Performance standards for antimicrobial susceptibility testing
Mary Jane. Ferraro
- 01 Jan 2001
TL;DR: The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.
23.8K
•Book
Performance standards for antimicrobial susceptibility testing
Melvin P. Weinstein,Clinical +1 more
- 01 Jan 2019
TL;DR: The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most recent editions of M02, M07, and M11, and users should replace outdated editions with the current editions of CLSI documents.
6.2K
Acinetobacter baumannii: Emergence of a Successful Pathogen
TL;DR: This review details the significant advances that have been made in understanding of this remarkable organism over the last 10 years, including current taxonomy and species identification, issues with susceptibility testing, mechanisms of antibiotic resistance, global epidemiology, clinical impact of infection, host-pathogen interactions, and infection control and therapeutic considerations.
3.3K
Multiplex PCR for detection of acquired carbapenemase genes
TL;DR: A rapid and reliable PCR-based technique was developed for detection of genes encoding carbapenemases belonging to different classes using optimized conditions, with PCR giving distinct amplicon sizes corresponding to the different genes for each mixture.
1.8K
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology
Laurent Poirel,Patrice Nordmann +1 more
TL;DR: In addition to beta-lactamases, carbapenem resistance in A. baumannii may also result from porin or penicillin-binding protein modifications, and several porins, including the 33-kDa CarO protein, that constitute a pore channel for influx ofcarbapenems, might be involved in carbapanem resistance.
1K